Cynthia Tate

Title: Cynthia Tate: Innovator in HTLV-II Detection Methods

Introduction

Cynthia Tate is a notable inventor based in Chicago, IL (US). She has made significant contributions to the field of virology, particularly in the detection of HTLV-II antibodies. Her work has implications for understanding and diagnosing conditions related to this virus.

Latest Patents

Cynthia Tate holds a patent for "Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides." This invention relates to a novel human T-cell lymphotropic virus type II (HTLV-II) isolate designated NRA. The isolate was originally obtained from a patient with atypical hairy cell leukemia. Preliminary analysis indicated that it differs genetically from the prototypical HTLV-II isolate Mo. The invention focuses on the gp46 and p21 envelope proteins encoded by the env gene. Additionally, it describes methods and kits for the detection of HTLV-II antibodies using these envelope proteins.

Career Highlights

Cynthia is associated with Abbott Laboratories Corporation, where she has been able to apply her expertise in virology and contribute to innovative solutions in healthcare. Her work has been instrumental in advancing the understanding of HTLV-II and its implications for human health.

Collaborations

Cynthia has collaborated with notable colleagues, including Helen H Lee and Priscilla Swanson. These partnerships have enhanced her research and contributed to the development of effective detection methods for HTLV-II.

Conclusion

Cynthia Tate's innovative work in the detection of HTLV-II antibodies showcases her dedication to advancing medical science. Her contributions are vital for improving diagnostic methods and understanding viral infections.